Angiotensin Peptides as Potentiators of SARS-CoV-2 Spike–AXL Interaction: Mechanistic Insights

Study Background and Research Question

The SARS-CoV-2 virus, responsible for the COVID-19 pandemic, achieves host cell entry primarily through the spike glycoprotein's interaction with cellular receptors. While angiotensin-converting enzyme 2 (ACE2) is the most recognized entry point, alternative receptors such as neuropilin-1 (NRP1) and AXL have been identified, particularly in cell types with low ACE2 expression (paper). The renin-angiotensin-aldosterone system (RAAS), which regulates cardiovascular and renal physiology, generates a variety of bioactive peptides, including angiotensin II and its metabolites. The interplay between these peptides and SARS-CoV-2 receptor binding, however, remains incompletely understood. Oliveira et al. (2025) addressed whether naturally occurring angiotensin peptides modulate spike protein binding to its known receptors, with a particular focus on the AXL receptor (paper).

Key Innovation from the Reference Study

The pivotal contribution of this research lies in systematically mapping the effects of various endogenous angiotensin peptides—including N- and C-terminally truncated forms—on the binding affinity between the SARS-CoV-2 spike protein and its receptors. Notably, the study uncovers that shorter angiotensin fragments, especially those lacking N-terminal residues such as Angiotensin III (sequence: Arg-Val-Tyr-Ile-His-Pro-Phe), markedly enhance spike–AXL binding. This expands the conceptual framework linking RAAS peptides not only to vascular homeostasis but also to viral entry mechanisms (paper).

Methods and Experimental Design Insights

The authors employed antibody-based binding assays to quantify the interaction between recombinant SARS-CoV-2 spike protein and its cellular receptors (AXL, ACE2, NRP1) in the presence of distinct angiotensin-derived peptides. The experimental design included:

• Testing full-length angiotensin I (1–10), angiotensin II (1–8), and shorter peptides produced by N- or C-terminal cleavage.
• Comparing effects of point mutations and phosphorylation at key residues (e.g., Tyr4 in angiotensin II).
• Quantifying changes in spike–receptor binding via ELISA-based detection and normalization to control conditions (paper).

By dissecting the structural requirements for spike–AXL binding enhancement, the study provides a mechanistic map of peptide-receptor-virus crosstalk.

Core Findings and Why They Matter

Several key results emerged:

• Angiotensin II (1–8) nearly doubled spike–AXL binding, without affecting spike–ACE2 or spike–NRP1 interactions.
• Angiotensin III (2–8), produced by N-terminal cleavage, further potentiated spike–AXL binding compared to angiotensin II, indicating the critical role of N-terminal truncation. Angiotensin IV (3–8) elicited an even stronger effect (up to a 2.7-fold increase in spike–AXL binding) (paper).
• C-terminal truncations (e.g., angiotensin (1–7), angiotensin (1–6)) preserved binding enhancement but did not surpass angiotensin II.
• Modifications at Tyr4 (substitution or phosphorylation) amplified spike–AXL binding, highlighting a structure-activity relationship.
• Only certain truncated peptides (not full-length angiotensin I) influenced spike–receptor binding, underscoring specificity tied to sequence length and composition.

These findings are significant for several reasons. First, they suggest that physiological or pathological shifts in the spectrum of circulating angiotensin peptides could directly impact viral entry propensity via AXL. Second, they spotlight angiotensin III and related fragments as potential molecular bridges between cardiovascular homeostasis and viral susceptibility (paper).

Comparison with Existing Internal Articles

Recent internal reviews have highlighted the multifaceted role of Angiotensin III in cardiovascular and neuroendocrine research. For example, the article "Angiotensin III: Advanced Mechanistic Insights and Novel ..." elaborates on the peptide's selective engagement with AT2 receptors and its dual capacity as a pressor activity mediator and aldosterone secretion inducer. While such resources detail Angiotensin III's canonical roles within the RAAS, the reference study by Oliveira et al. extends the mechanistic landscape by linking Angiotensin III to viral pathogenesis—a domain not deeply explored in cardiovascular literature (internal_article).

Similarly, "Angiotensin III (human, mouse): Molecular Gateway to Advanced Cardiovascular and Neuroendocrine Research" addresses translational opportunities in disease modeling, but the cross-domain impact revealed in the current reference study—specifically the peptide's ability to modulate viral receptor interactions—represents a substantial expansion of Angiotensin III's functional relevance (internal_article).

Protocol Parameters

• assay | ELISA-based spike–receptor binding | applicable to peptide–protein interaction quantification | enables quantitative assessment of peptide effects on viral binding to host receptors | paper
• peptide concentration | typically micromolar range (workflow_recommendation) | context-dependent; titrate to optimize signal | based on prior literature and empirical titration | workflow_recommendation
• solvent selection | DMSO ≥93.1 mg/mL, water ≥23.2 mg/mL, ethanol ≥43.8 mg/mL | suitable for dissolving Angiotensin III | high solubility ensures reproducibility across assay types | product_spec
• storage conditions | -20°C, desiccated | preserves peptide integrity | minimize freeze-thaw cycles and avoid long-term solution storage | product_spec

Limitations and Transferability

While the study convincingly demonstrates that certain angiotensin peptides enhance SARS-CoV-2 spike binding to AXL in vitro, several limitations merit consideration. The binding assays were conducted with recombinant proteins under controlled conditions, and do not directly assess downstream infection efficiency or in vivo relevance. Furthermore, the precise tissue concentrations and distribution of truncated angiotensin peptides during physiological or pathological states remain to be quantified. Translating these findings to models of infection or clinical settings will require additional studies addressing peptide pharmacokinetics, receptor expression profiles, and the impact of comorbidities (paper).

Why this cross-domain matters, maturity, and limitations

This research bridges cardiovascular peptide biology and infectious disease by elucidating how RAAS-derived peptides, such as Angiotensin III, can modulate viral entry mechanisms. The maturity of this bridge remains early-stage; the mechanistic link is established at the binding level, but functional consequences for viral replication and clinical outcomes are yet to be determined. These cross-domain insights prompt new questions about the interplay between cardiovascular regulation and respiratory viral pathogenesis (paper).

Research Support Resources

For laboratories aiming to investigate the intersection of RAAS peptides and viral receptor interactions, high-purity Angiotensin III (human, mouse) (SKU A1043) is available from APExBIO. Its validated sequence (Arg-Val-Tyr-Ile-His-Pro-Phe), robust solubility profile, and quality control make it suitable for assays exploring peptide-mediated modulation of spike–AXL binding or for broader cardiovascular research applications. Researchers are encouraged to optimize protocols to their specific systems and consult primary literature for guidance (product_spec).